9 articles
Medicare covers Ozempic for type 2 diabetes but not for weight loss. Here's what the 2026 Part D rules mean for seniors, and how the July 2026 GLP-1 Bridge will change coverage for Wegovy and Zepbound.
What 4-5 years of randomized and real-world data actually show about long-term Ozempic/semaglutide use: cardiovascular protection, kidney outcomes, thyroid risk reassessment, muscle-mass trajectory, and weight regain after discontinuation.
Yes — insurance evaluates the prescription, not where it was prescribed. Here is how telehealth and insurance work together for Ozempic.
Ozempic is FDA-approved for diabetes, not weight loss — so most insurers deny it for weight management. Here are your options.
A comprehensive guide to what you'll actually pay for Ozempic, Wegovy, Mounjaro, and Zepbound with insurance, Medicare, Medicaid, and self-pay options. Pricing verified April 2026.
A 2025 cohort of 1+ million matched patients found GLP-1 users had 40% higher odds of hair loss at 12 months — mostly reversible telogen effluvium triggered by rapid weight loss. Here's what the research actually shows.
Nausea affects 20–40% of GLP-1 users but is mostly mild, peaks during dose escalation, and fades within weeks. Here's what 8 clinical studies and thousands of real users reveal about why it happens and how to manage it.
You need 1.2–1.6g of protein per kg of body weight daily on a GLP-1 medication. Here's what 261 clinical studies and 2,000+ real users reveal about protein targets and muscle preservation.
No articles in this category yet.